Allergan plc, formerly Actavis plc, is a global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name, medical aesthetics, generic, branded generic, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through five segments: US Brands, US Medical Aesthetics, International Brands, Global Generics and Anda Distribution. The Company's brand portfolio includes franchises in therapeutic categories, such as ophthalmology, neurosciences, medical aesthetics/dermatology/plastic surgery, central nervous system (CNS), gastroenterology (GI), women's health and urology disease. In addition, the Company offers GLYX-13, a once-weekly intravenous Phase III-ready molecule that has demonstrated efficacy in multiple Phase II clinical studies in depression, and NRX-1074, an orally bioavailable drug candidate which is in Phase I studies.